Catalyst Wire Dossier Catalyst Wire Dossier

bb2121 (idecabtagene vicleucel)

idecabtagene vicleucel · Bristol Myers Squibb
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for bb2121 (idecabtagene vicleucel), covering 2026-03-04 to 2026-03-04. Get the full timeline:

Most recent: Clinical Trial Update: An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma [Phase 2]

See pricing